-
2 weeks ago | 
drugtopics.com | Brian Nowosielski |Marta Wosinska |Joey Mattingly
As their impacts on American businesses are still being understood, the potential role US tariffs may play within the US pharmaceutical market could have detrimental impact on both patients as well as the pharmacies and pharmacists that dispense medications. “If there's a tariff, somebody is going to have to absorb it. Somebody is going to have to pay for it,” said Marta Wosinska, PhD, senior fellow with The Brookings Institution. “The question [is] who is it going to be?
-
3 weeks ago | 
drugtopics.com | Brian Nowosielski |Marta Wosinska |Joey Mattingly
While not yet imposed—and with great uncertainty regarding widespread implementation—many pharmacy industry experts are scrambling to understand the true impact of pharmaceutical tariffs should they be enacted. However, until they are widespread across the country, experts are urging pharmacies to advocate against these tariffs while also preparing for their implementation.
-
4 weeks ago | 
drugtopics.com | Brian Nowosielski |Marta Wosinska |Joey Mattingly
When it comes to the US imposing tariffs within any sector of American business, there are specific entities that will be forced to absorb costs and essentially lose money. In the case of pharmaceuticals, tariffs could cause immense jumps in drug prices, in turn, creating a greater challenge for pharmacies to stay financially sustainable and keep their necessary inventory in optimal supply. “If there's a tariff, somebody is going to have to absorb it.
-
Jul 5, 2024 | 
brookings.edu | Marta Wosinska |Richard Frank
Marta Wosińska and Richard Frank recently commented on a Senate Finance Committee legislative draft proposing a Medicare Drug Shortage Prevention and Mitigation Program (“Shortage Program”) and an exemption from Medicaid inflation rebates for multisource generics.
-
Mar 13, 2024 | 
brookings.edu | Marta Wosinska
High-profile shortages of amoxicillin, cancer drugs, and medications to treat attention deficit hyperactive disorder (ADHD) have put drug shortages in the headlines over the past year. Less visible but equally alarming have been shortages of lifesaving emergency drugs such as atropine and epinephrine. Many of these shortages are persistent. These shortages throw into question the reliability of the U.S. drug supply chain.
-
Jan 11, 2024 | 
brookings.edu | Marta Wosinska |Rena Conti |Elisabeth B. Reynolds
On March 2, 2023, the authors convened a group of experts from academia, industry, government, and nonprofits to explore technology options for increasing the resilience in the supply of generic prescription drugs. The workshop was convened at the Massachusetts Institute of Technology with the help of the National Network for Critical Technology Assessment and financial support from the Alfred P. Sloan Foundation. This report, authored by the organizers, summarizes the discussion.
-
Dec 5, 2023 | 
brookings.edu | Marta Wosinska
Editor's note: The following testimony was given to the Senate Committee on Finance on December 5, 2023. The original version of the submitted testimony and a video of the hearing is available here. The version below was edited for clarity and accuracy. Chairman Wyden, Ranking Member Crapo, and members of the Committee, thank you for inviting me here today.
-
Nov 1, 2023 | 
brookings.edu | Marta Wosinska |Rena Conti
In October 2023, Marta Wosińska and Rena Conti concluded a one-year pilot demonstration of how analytics can inform national technology strategy in biopharmaceuticals. Their demonstration was part of a large, cross-industry pilot titled the National Network for Critical Technology Assessment.
-
Sep 13, 2023 | 
healthaffairs.org | Marta Wosinska |Rena Conti
The assured, consistent availability of pharmaceuticals is a cornerstone for patient wellbeing, effective treatment, and equal access to needed medical care. Pharmaceutical supply disruptions compromise medical care and may place patients’ health and even their lives at risk through treatment delays, rationing, increased likelihood of medication errors, and the substitution of possibly inferior alternatives. Yet, pharmaceutical supply chains in the United States (US) are vulnerable to disruptions.
-
Jul 12, 2023 | 
brookings.edu | Marta Wosinska |Richard Frank
Marta Wosińska and Richard Frank recently responded to a request for information from the Senate Finance Committee and the House Energy and Commerce Committee seeking input from stakeholders on persistent drug shortages. Their response addresses the economic and market conditions that lead to underinvestment in quality manufacturing operations and, with that, shortages.
